At AAN 2024, Axsome Therapeutics presented new pooled data from two Phase III trials evaluating AXS-07 as an acute treatment for migraine in a poster session. The post AAN 2024: new pooled data highlights efficacy of Axsome Therapeutics’s AXS-07 appeared first on Clinical Trials Arena ..read more

The 18-month research project aims to identify key moments when the condition progresses to enable better treatment plans. The post gaitQ and machineMD secure $1m to kickstart Parkinson’s movement study  appeared first on Clinical Trials Arena ..read more

Artiva has announced dosing of the first subject in the Phase I clinical trial of AlloNK for the treatment of lupus nephritis (LN). The post Artiva doses first subject in Phase I lupus nephritis treatment trial appeared first on Clinical Trials Arena ..read more

Roche has reported data from the Phase III trial of OCREVUS SC in individuals with relapsing or primary progressive multiple sclerosis. The post Roche’s OCREVUS SC shows promise in Phase III multiple sclerosis trial appeared first on Clinical Trials Arena ..read more

Joincare will file an NDA in China while TaiGen will continue development of TG-1000 in the US, Europe and other Asian countries. The post Joincare Pharmaceutical meets primary endpoint in Phase III flu trial appeared first on Clinical Trials Arena ..read more

GSK has announced positive data from the Phase III EAGLE-1 trial of gepotidacin for gonorrhoea in adolescent and adult patients. The post GSK reports positive data from Phase III gonorrhoea antibiotic trial appeared first on Clinical Trials Arena ..read more

At AAN 2024, AbbVie highlighted the long-term safety data of Qulipta (atogepant) for the preventive treatment of migraines. The post AAN 2024: AbbVie highlights long-term safety of atogepant in migraine prevention appeared first on Clinical Trials Arena ..read more

On 15 April at the American Academy of Neurology (AAN) 2024 Annual Meeting, during a scientific platform session titled 'Emerging Science', Alzheon presented results from its Phase II Biomarker Trial and reviewed its APOLLOE4 Phase III Trial both evaluating its oral, brain-penetrant, amyloid-oligomer inhibitor ALZ-801 in apolipoprotein E 4 (APOE4) carrier patients with early Alzheimer’s disease (AD). The post AAN 2024: Biomarker data shows promise for Alzheon’s oral anti-amyloid drug appeared first on Clinical Trials Arena ..read more

At the American Academy of Neurology (AAN) 2024 Annual Meeting, Amneal Pharmaceuticals presented new safety data for IPX203 (carbidopa + levodopa, CD/LD) from its Phase III clinical trial RISE-PD and open-label extension in Parkinson’s disease (PD) patients with motor fluctuations. The post AAN 2024: Amneal showcases IPX203’s safety profile in anticipation of FDA approval appeared first on Clinical Trials Arena ..read more

Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The post Ultimovacs downsizes to funnel funds to cancer vaccine programme appeared first on Clinical Trials Arena ..read more